Drug Profile
Research programme: stem cell therapies - Gamida-Cell
Alternative Names: GC-003Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Gamida-Cell
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute radiation syndrome; Cardiovascular disorders; Crohn's disease; Diabetes mellitus; Graft-versus-host disease; Musculoskeletal disorders; Neutropenia; Vascular disorders
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in Israel
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Israel
- 28 Dec 2021 No recent reports of development identified for preclinical development in Crohn's-disease in Israel